You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
CGP 36216 hydrochloride
Selective GABAB antagonist. Displays activity at presynaptic receptors; ineffective at GABAB postsynaptic receptors.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 187.6. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.33 mL||26.65 mL||53.3 mL|
|5 mM||1.07 mL||5.33 mL||10.66 mL|
|10 mM||0.53 mL||2.67 mL||5.33 mL|
|50 mM||0.11 mL||0.53 mL||1.07 mL|
References are publications that support the biological activity of the product.
Ong et al (2001) CGP 36216 is a selective antagonist at GABAB presynaptic receptors in rat brain. Eur.J.Pharmacol. 415 191 PMID: 11274998
Froestl et al (1995) Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J.Med.Chem. 38 3313 PMID: 7650685
If you know of a relevant reference for CGP 36216 hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CGP 36216 hydrochloride, CGP 36216 hydrochloride supplier, CGP36216, hydrochloride, gabab, antagonists, presynaptic, selective, GABAB, Receptors, 3219, Tocris Bioscience
1 Citation for CGP 36216 hydrochloride
Citations are publications that use Tocris products. Selected citations for CGP 36216 hydrochloride include:
Chen et al (2015) Morphine disinhibits glutamatergic input to VTA DA neurons and promotes DA neuron excitation. J Neurosci 4 PMID: 26208338
Do you know of a great paper that uses CGP 36216 hydrochloride from Tocris? Please let us know.
Reviews for CGP 36216 hydrochloride
There are currently no reviews for this product. Be the first to review CGP 36216 hydrochloride and earn rewards!
Have you used CGP 36216 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.